Skip to content
Roboearth – Lifestyle
Author:
Deep Origin
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
October 14, 2026
Drug Developers Deploy In Silico Drug Safety Prediction Models From Deep Origin’s ARPA-H-Funded PREDICTS Consortium
September 24, 2026
Deep Origin Introduces Novel Virtual Screening Architecture; Achieves 100-fold Hit Rate Jump on Challenging Target
August 5, 2026
Deep Origin’s Computational Platform Rationalizes Results of Molecular Glue Compound That Potently Kills Diffuse Large B Cell Lymphoma Cells
July 20, 2026
Deep Origin Promotes Natalie Ma, PhD, to Chief Business Officer as Company Advances Computational Drug Discovery Platform
March 17, 2026